VERUS INTERNATIONAL, INC. REPORTS 101% INCREASE IN ANNUAL

New Post Public Reply Private Reply Replies (0) Message Board
NotRichYet2 NotRichYet2 #46861
266
VERUS INTERNATIONAL, INC. REPORTS 101% INCREASE IN ANNUAL REVENUE



March 19, 2019 17:30 ET | Source: Verus International, Inc.
Gaithersburg, MD, March 19, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) today announced financial results for its fiscal 2018 fourth quarter and full year ended October 31, 2018. In conjunction with this release, the Company will also provide additional details on its strategy for fiscal 2019.

For the full year, management is noting the following items of importance:

In fiscal 2018, Verus posted sales of $5.8 million, a 101% increase over the $2.9 million registered in fiscal 2017.
The company’s gross margin averaged 12.9%, within the higher range of expectations.
Total operating expenses increased slightly by 4% to $1.7 million compared to $1.6 million in fiscal 2017.
As of October 31, 2018, the Company had sold approximately $8.2 million in products pursuant to its original $79 million buffalo order.
Investors should be aware that a large, negative charge ($0.9 million) listed as “default principal increase on convertible notes payable” will be reversed in the 2nd quarter Form 10-Q, as these penalty provisions were extinguished subsequent to the fiscal year end.
Highlights from Q4, Fiscal 2018 include the following:

Q4/18 revenue was the highest in company history at $2.2 million, marking a 134% increase over last year (Q4/17) and a 60% increase over the preceding quarter (Q3/18)
Q4/18 gross margins where within the expected higher range for the current product mix, coming in at close to 11.6%
“The fiscal 2018 10-K is a true look back in time, because it still includes the impact of the legacy real estate business and negative provisions from the convertible debt. So, the Q4 portion of this release is a better indicator of things to come,” explained Verus CEO Anshu Bhatnagar. “In Q4 we began shipping on our multiproduct order, which commenced part way through the quarter. Sales will accelerate even faster as our newest orders begin to ship in upcoming months. Perhaps most importantly, investors got a glimpse of how close Verus is to profitability, without the finance and equity related changes, this would have been a profitable quarter.”

On a forward basis, the Company would like to provide the following update:

Verus is projecting that quarterly sales will grow in excess of 100% on a year over year basis and accelerate significantly throughout fiscal 2019
The Company is currently in negotiations for new contracts in both its core markets and other markets that would represent an expansion of the current product portfolio
With completion of the recent recapitalization, Verus has reinitiated discussions with commercial banks and other sources of non-dilutive financing
In terms of potential mergers and acquisitions, Verus is conducting due diligence on seven candidates and is moving forward on several of these companies. It is not possible to say how many of these candidates will become operating subsidiaries until final negotiations are completed.
Verus is approached almost weekly with partnership, acquisition, distribution and similar growth opportunities, so the consumer products space continues to show robust activity.
“Today’s update should be considered Part One, because the recap delay in filing our annual report has us bumping into the first quarter report for fiscal 2019, giving us the unusual case of near back-to-back financials,” said CEO Bhatnagar. “Because I have so many growth initiatives pending and we have fresh financials so close at hand, I have decided to resume our traditional earnings call format to coincide with our upcoming Q1/19 quarterly release, which is already in work. That will give me a little extra time to complete some important initiatives and provide us with more relevant financials to discuss.”

“Looking back at fiscal 2018, investors should be encouraged at how strongly we finished in Q4, despite operating the entire year under a dark cloud of uncertainty. With the recap completed, that uncertainty is gone and I can now concentrate on growing the business. I just completed my most successful business trip, to Dubai and India, since founding Verus. The results of that trip have already been seen in some recent orders, but those are just the beginning. Our pending book of business gives me great confidence in projecting accelerating triple-digit growth throughout 2019.”

The Company will return to a more normalized financial reporting format with the upcoming fiscal 2019 Q1 filing. In conjunction with that report, Verus will conduct an earnings call and provide additional commentary on expectations for 2019.

Interested investors are reminded to watch for product updates on the official Twitter feed @V

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sean Trahan Joins Citrin Cooperman: New Tax Lead

Updated Category News Views 7

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Continue Reading
Davos Healthcare Aims to Revolutionize Hospital Ratings

Updated Category News Views 6

Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...

Continue Reading
AI-Driven Lumi Transforms Car Dealership Interactions

Updated Category News Views 7

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

Continue Reading
Dr. Desi Bartlett Teams Up with Glo for Perimenopause Focus

Updated Category News Views 4

Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...

Continue Reading
FJBio Boosts Antibody Discovery with Sapio AI

Updated Category News Views 5

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...

Continue Reading
Cracking the Code of America's Delivery Addiction

Updated Category News Views 4

America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...

Continue Reading
Succession Planning in Turmoil: Only 42% Ready

Updated Category News Views 5

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

Continue Reading
The Chemical Industry and EPA: A Broken System?

Updated Category News Views 6

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Continue Reading
Leapora's Taskeen: Redefining Task Accountability

Updated Category News Views 5

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Continue Reading
FutureVault's AI Agents: Transforming Financial Workflows

Updated Category News Views 4

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

Continue Reading

Top 5 Most Recently Viewed Articles

PMGC Capital's Strategic Investment in Alaunos Therapeutics

Updated Category News Views 171

PMGC Capital LLC Plans to File Schedule 13D on Alaunos PMGC Capital LLC, a fully owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), has made a significant move in the financial landscape by announcing its intention to file a Schedule 13D with the U.S. Securities and Exchange Commission (SEC). This filing will disclose its beneficial ownership in Alaunos Therapeutics,...

Continue Reading
Black Diamond Therapeutics: Pivotal Developments Ahead

Updated Category News Views 97

Black Diamond Therapeutics Continues to Make Strides Recently, H.C. Wainwright confirmed a Buy rating on Black Diamond Therapeutics (NASDAQ: BDTX) shares, projecting a price target of $11.00. This positive outlook follows the company's major restructuring efforts aimed at advancing BDTX-1535, its leading drug candidate, into pivotal trials. This move is expected to not...

Continue Reading
Eureka Acquisition Corp Announces New Meeting Date and Deadlines

Updated Category News Views 187

Eureka Acquisition Corp's Important Announcement New York — Eureka Acquisition Corp (NASDAQ: EURK), a special purpose acquisition company, has recently made significant announcements regarding the schedule of its extraordinary general meeting. Originally set for June 20, it will now take place on June 25, providing shareholders with extra time for participation. Details...

Continue Reading
Diamedica Therapeutics Hits New Heights with $6.41 Stock Value

Updated Category News Views 118

Diamedica Therapeutics Inc. Achieves 52-Week High Diamedica Therapeutics Inc. (NASDAQ: DMAC) is making headlines as its stock has recently hit a remarkable 52-week high of $6.41. This impressive milestone comes amid a significant growth phase for the company, which is currently valued at around $230 million. The steep rise in the stock price over the past year indicates a...

Continue Reading
J.P. Morgan's Projections for 2025: Capital Market Insights

Updated Category News Views 6083

J.P. Morgan's Capital Market Assumptions for 2025 J.P. Morgan Asset Management has recently unveiled its 2025 Long-Term Capital Market Assumptions (LTCMAs), providing valuable insights into the anticipated returns and risks across various asset classes for the next decade. These projections serve as a compass for investment strategies, targeting institutional and...

Continue Reading